Poseida Therapeutics CEO Mark Gergen's 2022 pay jumps 55% to $4.4M
Poseida Therapeutics reports 2022 executive compensation
By ExecPay News
Published: April 26, 2023
Poseida Therapeutics reported fiscal year 2022 executive compensation information on April 26, 2023.
In 2022, four executives at Poseida Therapeutics received on average a compensation package of $2.4M, a 22% decrease compared to previous year.
Average pay of disclosed executives at Poseida Therapeutics
Mark J. Gergen, Chief Executive Officer, received $4.4M in total, which increased by 55% compared to 2021. 40% of Gergen's compensation, or $1.8M, was in option awards. Gergen also received $342K in non-equity incentive plan, $566K in salary, $1.7M in stock awards, as well as $13K in other compensation.
Brent Warner, President, Gene Therapy, received a compensation package of $2.9M. 37% of the compensation package, or $1.1M, was in stock awards.
Eric Ostertag, Chief Executive Officer, earned $1.3M in 2022, a 79% decrease compared to previous year.
Harry J. Leonhardt, General Counsel, received $978K in 2022, which decreases by 32% compared to 2021.
Related executives
You may also like
Source: SEC filing on April 26, 2023.